Anthropic CEO Dario Amodei tells IPO investors AI will end cancer within a decade

Anthropic has spent years presenting its chief executive as the careful one among the people building advanced AI. This week, in a video made to sell shares, Dario Amodei told prospective investors that cancer, Alzheimer’s, heart disease and mental illness will be “relics of the past” in less than a decade. The sentence is not new for him. The setting is. A roadshow is where a company asks for money, and a cure timeline is the most valuable promise anyone in medicine can make.

Doctors and a biotech executive have pushed back, and so, in effect, has Amodei’s own record. Earlier this year he wrote that saying AI will cure cancer had become a cliché most people find deceptive. Almost nobody disputes that AI can help medicine. The real question is which part of a drug pipeline that runs for years his company can actually shorten, and on what evidence.

What Amodei told investors

Anthropic began marketing its shares on November 10 with a roadshow video of roughly 42 minutes, TNW and TechSpot reported. In it, Amodei named four diseases. “You know, if today we look at things like cancer, Alzheimer’s, heart disease, mental illness, these will be relics of the past in, I think, less than a decade,” he said. Then he widened the frame: “I think if we do this right, we can create an age of miracles where humanity is able to solve problems that have eluded us for millennia.”

He tied the promise to safety. The company that gets the risks right, he said, will be the one with “the license to operate that society trusts.” The founders’ letter to investors, published with the original IPO filing, makes the medical case in calmer language, saying AI could “bring cures for major diseases within reach.” The same letter lists “underpromise and overdeliver” among Anthropic’s guiding principles, as TNW pointed out.

The pushback came from medicine

Karl Lauterbach, a physician and epidemiologist who served as Germany’s health minister, answered on X that AI can help research into cancer, Alzheimer’s and mental illness, but that curing them within ten years is impossible. He asked whether people like Amodei know little about medicine or are misleading the public, according to TNW’s translation of his post, and argued the focus should be on prevention.

Melinda B. Chu, a doctor and AI medical researcher at Saint Louis University, told Business Insider that “Anthropic has done nothing to suggest they themselves will contribute meaningfully to these goals.” Biotech executive Rami Elghandour went after the venue. “I’ve taken two companies public. These are insane things to say in an IPO pitch,” he said, as quoted by Business Insider. On X, according to TechSpot, he said the remarks reek “of desperation.”

Drug makers have been sceptical of the pace for a while. Jeff Leiden, executive chairman of Vertex Pharmaceuticals, told The Wall Street Journal that Vertex had evaluated about 50 AI companies against a database of 10,000 compounds and that none had independently generated a working drug, The American Bazaar reported.

Amodei already named the problem

The sharpest rebuttal comes from Amodei himself. In an X post in August, he wrote that “at this point, saying that AI will cure cancer is more a cliche than it is inspiring, and most people think it is deceptive.” He added that “the thing that will work is actually curing cancer,” and that the most accurate criticism of AI companies, Anthropic included, is that “we haven’t yet delivered on our big promises to benefit the world,” as Transformer reported at the time.

Three months later the same promise is back, this time with a deadline, inside the material built to sell his company’s stock. That shift is the mechanism worth watching. In an essay, “within a decade” is a vision. In a share sale, it becomes a forecast that buyers fold into a price. Investors are not being asked whether AI is useful in a lab. They are being asked to put a value on a date.

What Anthropic’s labs can show so far

Anthropic does have a medical programme, and it is real but early. In an October 27 company update, it said it had research partnerships with six organisations developing medicines and had started drug discovery programmes of its own, including work on rare childhood diseases such as forms of muscular dystrophy. It acknowledged that most of this work is still preclinical, meaning it has not reached human testing, The American Bazaar reported. In October it also bought a one-person biotech start-up working on muscular dystrophy, according to Business Insider as cited by TNW.

The founders’ letter points to operational wins. The World Health Organization’s Regional Office for Africa used Claude during the Ebola outbreak in the Democratic Republic of the Congo, cutting its daily situation report from a full day to under an hour. With the Gates Foundation, Anthropic supports free AI clinical search for doctors in roughly 100 low- and middle-income countries.

Those results matter, and none of them is a cure. The wider record is the one critics keep citing. After more than a decade of effort, no AI-designed drug has reached clinical adoption, and AlphaFold, the field’s best-known success, has yet to produce an approved medicine, AI Weekly noted in summarising reporting by The Information. As Transformer put it, cells do not divide instantly and mice need time to reproduce. A model can propose a molecule in seconds, but a clinical trial still runs on human time.

The test after the listing

Anthropic’s shares are due to start trading on Nasdaq on November 19. Amodei is not alone in this pitch: Google DeepMind’s Demis Hassabis has suggested AI could cut drug development from about ten years to months, The American Bazaar reported, and OpenAI president Greg Brockman said last week that AI will make significant strides in biology and health over the next 12 to 18 months, TechSpot reported. But only one of those companies has now put the promise in front of IPO buyers.

The first honest checkpoint will not be a cure. It will be the day one of Anthropic’s preclinical programmes moves a molecule into a human trial, and that date appears nowhere in the pitch.

Tags: Anthropic, Claude, Dario Amodei, cancer, drug discovery